RenovoRx Roars into Commercial Phase with Strong First Year of RenovoCath Adoption

The year 2025 marked a significant milestone for RenovoRx, as it transitioned from a clinical development phase to commercialization with its patented TAMP therapy platform.

Speaking at the company's Q4 2025 financial results conference call, CEO Shaun Bagai emphasized that this evolution reflects a deliberate and positive step in the company's maturation. He noted that RenovoRx has positioned itself as a commercial stage growth company, with Dr. Ramtin Agah, the founder and inventor of the TAMP therapy platform, transitioning to the role of Executive Chairman.

Bagai highlighted the importance of Agah's leadership in driving commercial efforts at both the physician-to-physician level and shaping the company's commercial strategy. He also welcomed Mark Voll as the new Chief Financial Officer, citing his extensive experience in guiding high-growth public companies through periods of commercial build-out and strategic development.

RenovoRx entered 2025 with limited approved commercial cancer centers and no dedicated sales team but exited the year with a strong understanding of the market and a clear strategy supported by a focused and agile sales and marketing team. The company generated over $1 million in revenue for the full year, reflecting strong initial adoption of its RenovoCath product.

The fourth quarter revenues came in at $238,000, tracking closely to Q3 results. Bagai explained that this was due to a small number of active commercial centers and the variability that comes with a new product launch. However, he emphasized that the revenue is not a reflection of physician demand, product satisfaction, or the long-term commercial opportunity.

Despite the scale limitations, RenovoRx reported positive market penetration in 2025. The company currently has 17 phase III TIGeR-PaC sites that have used RenovoCath in the trial and are preparing to transition to commercial use upon enrollment completion.

The strong foundation laid by RenovoRx's first year of commercialization paves the way for continued growth and expansion into new markets. As the company looks ahead to 2026, investors can expect significant strides in scaling operations and further development of its TAMP therapy platform.

Bagai concluded that RenovoRx is well-positioned to capitalize on the growing demand for innovative cancer treatments, driven by a dedicated leadership team and a clear commercial strategy. The company's commitment to delivering value to patients, physicians, and shareholders remains unwavering as it enters this exciting new phase of growth.

The conference call provided valuable insights into RenovoRx's financial performance and strategic plans, solidifying the company's position as a leader in the cancer treatment industry.